The HINT2 Knockout HT29 Polyclonal Cells product consists of a polyclonal population of HT29 human colorectal adenocarcinoma cells engineered via CRISPR/Cas9 to disrupt the HINT2 gene. This polyclonal knockout cell population provides a heterogeneous loss-of-function model, reflecting a range of editing events across the cell pool, avoiding clonal bias. By eliminating HINT2 expression, this tool facilitates the study of mitochondrial apoptosis and tumor-suppressive mechanisms in colorectal cancer research.
HT29 cells are a well-characterized epithelial cell line isolated from a primary colorectal adenocarcinoma of a 44-year-old female. These adherent cells retain the capacity to differentiate into enterocyte-like and mucus-secreting phenotypes under specific culture conditions, making them a robust model for intestinal epithelial biology and colorectal tumorigenesis. The HT29 background is frequently employed in studies of drug response, epithelial barrier function, and oncogenic signaling, providing a physiologically relevant context for tumor suppressor gene investigation.
HINT2 encodes a histidine triad nucleotide-binding protein localized to the mitochondrial intermembrane space, where it functions as a hydrolase and critical modulator of intrinsic apoptosis. Acting downstream of p53 signaling, HINT2 promotes apoptosis by facilitating mitochondrial outer membrane permeabilization (MOMP) and the subsequent release of cytochrome c, which interacts with APAF1 to activate caspase-9 and downstream effector caspase-3. Concurrently, HINT2 interacts with BAX and BAK, enabling their pro-apoptotic oligomerization at the mitochondrial membrane. In colorectal tumors, HINT2 is frequently silenced via promoter hypermethylation, abrogating this tumor-suppressive pathway and contributing to enhanced cell survival and chemoresistance.
In the HT29 colorectal adenocarcinoma context, HINT2 knockout provides a powerful platform to dissect the contribution of HINT2 deficiency to cancer progression and therapeutic resistance. HT29 cells harbor wild-type TP53, and HINT2 loss in these cells recapitulates the epigenetic silencing observed in approximately 60% of colorectal carcinomas. This model enables researchers to examine how HINT2 ablation alters mitochondrial metabolism, reduces sensitivity to DNA-damaging agents, and rewires apoptotic signaling networks. Furthermore, the polyclonal nature of the knockout population better mirrors the genetic heterogeneity of tumor evolution, allowing robust functional genomics and drug screening studies.
Typical applications include western blotting and RT-qPCR to validate HINT2 knockdown and monitor downstream effectors such as cleaved caspase-3 and BAX levels, alongside caspase-3/7 activity assays and JC-1 mitochondrial membrane potential measurements. Proliferation (MTT/CCK-8) and colony formation assays quantify growth advantages, while Annexin V/PI flow cytometry directly measures apoptosis induction in response to chemotherapeutics. Methylation-specific PCR can assess promoter status, and Boyden chamber invasion assays probe metastatic potential. This knockout model is instrumental in epigenetic drug discovery, particularly for demethylating agent evaluation, and in dissecting the p53-HINT2-apoptosis axis. For further technical details or custom requests, please contact Ascent Research.
